Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyAlaska Medicaid Bimzelx Prior Auth Coverage | Open…
    Ask Trek AI about this page
    CurrentAlaska MedicaidPolicy N/A

    Bimzelx (bimekizumab) prior authorization — coverage criteria for plaque psoriasis, psoriatic arthritis, nr-axSpA, and ankylosing spondylitis

    Customize your policy alerts

    Sign up for all Alaska Medicaid policy alerts

    Know when Alaska Medicaid releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Alaska Medicaid prior authorization criteria, approval/denial rules, quantity limits, and required documentation for bimekizumab (Bimzelx) for indicated adult inflammatory conditions.

    Policy Summary
    PayerAlaska Medicaid
    PolicyBimzelx (bimekizumab) prior authorization — coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and submit required baseline documentation (PASI or CASPAR, current weight, liver function tests) to support approval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4FDA indications
    3 moInitial approval
    12 moReauthorization
    PSO:2 / others:1Quantity limits

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage / Medical Necessity Criteria

    Plaque Psoriasis

    Covered when ALL of the following are met

    PSO Approval: 1. Patient meets FDA labeled age
    PSO Prescriber: 2. Prescribed by or in consultation with a dermatologist
    PSO Disease Severity: 3. Patient has diagnosis of moderate to severe plaque psoriasis AND one or more of: a) Body Surface Area (BSA) ≥ 3% involved; b) Psoriasis Area and Severity Index (PASI) score ≥ 10; c) Concomitant severe psoriatic arthritis
    PSO Prior Therapy: 4. Patient has tried and failed or has a documented clinical contraindication to a TNF antagonist and at least one other therapy, including at least one topical agent
    PSO Baseline Information: 5. Prescriber has provided all the following baseline information: a) PASI score; b) Current patient weight; c) Liver function enzymes, alkaline phosphatase, and bilirubin

    Psoriatic Arthritis

    Covered when ALL of the following are met

    PsA Approval: 1. Patient meets FDA labeled age
    PsA Prescriber: 2. Prescribed by or in consultation with a dermatologist or rheumatologist
    PsA Diagnosis: 3. Patient has a CASPAR criteria score of ≥ 3 (or equivalent)
    PsA Prior Therapy: 4. Patient has tried and failed a preferred TNF antagonist and at least one conventional agent (e.g., methotrexate, sulfasalazine) for at least 3 months
    PsA Baseline Information: 5. Prescriber has provided all the following baseline information: a) CASPAR score (or equivalent); b) Current patient weight; c) Liver function enzymes, alkaline phosphatase, and bilirubin

    Non-radiographic Axial Spondyloarthritis

    Covered when ALL of the following are met

    nr-axSpA Approval: 1. Patient meets FDA labeled age
    nr-axSpA Prescriber: 2. Prescribed by or in consultation with a rheumatologist
    Objective Inflammation: 3. Patient has objective signs of inflammation, including at least one of: a) C-reactive protein (CRP) above the upper limit of normal; b) Sacroiliitis on MRI indicative of inflammatory disease without definitive radiographic structural damage of the sacroiliac joints
    nr-axSpA NSAID Trial: 4. Patient has tried and failed or has a documented clinical contraindication to 2 different NSAIDs for at least 3 months at maximal recommended or tolerated anti-inflammatory doses

    Ankylosing Spondylitis

    Covered when ALL of the following are met

    AS Approval: 1. Patient meets FDA labeled age
    AS Prescriber: 2. Prescribed by or in consultation with a rheumatologist
    AS Disease Severity: 3. Patient BASDAI score ≥ 4 with spinal pain component score ≥ 4
    AS NSAID Trial: 4. Patient has tried and failed or has a documented clinical contraindication to 2 different NSAIDs for at least 3 months at maximal recommended or tolerated anti-inflammatory doses
    AS TNF Trial: 5. Patient has tried and failed or has a documented clinical contraindication to a preferred TNF antagonist for at least 3 months

    Active inflammatory bowel disease (IBD) is an explicit exclusion to approval for bimekizumab. Requests for therapy will be denied if the patient has active IBD documented in the medical record.

    Therapy is not approved when the prior authorization approval criteria are not met. Requests will also be denied if the patient has an active clinically significant infection or is receiving another biologic response‑modifying agent, unless documentation demonstrates these conditions have been resolved or the concomitant therapy has been discontinued per prescribing guidance.

    Severity Thresholds and Coding-relevant Criteria

    Plaque Psoriasis severity thresholds
    Plaque psoriasis severity thresholdsBody Surface Area (BSA) ≥ 3% involved
    Psoriasis Area and Severity Index (PASI)PASI score ≥ 10
    Alternate qualifying conditionConcomitant severe psoriatic arthritis (meets criteria in policy)
    Ankylosing Spondylitis BASDAI
    BASDAI overall thresholdBASDAI score ≥ 4
    Spinal pain componentSpinal pain component score ≥ 4
    Combined requirement

    Prior Authorization, Step Therapy, Documentation, and Denial Conditions

    Prior Authorization

    Prior authorization required; approval conditioned on meeting indication criteria

    Prior authorization is required for bimekizumab; approval is granted only when the patient meets the diagnosis‑specific criteria listed in the coverage criteria sections for each indication.

    Step Therapy

    Step therapy: required prior trials or documented contraindication

    Patients must have tried and failed, or have a documented clinical contraindication to, the specified prior therapies outlined for each indication (examples include failure of a preferred TNF antagonist and other agents; for axial disease and ankylosing spondylitis, failure of two different NSAIDs).

    • Plaque psoriasis: tried and failed or documented contraindication to a TNF antagonist and at least one other therapy including at least one topical agent (chunk 4).
    • Psoriatic arthritis: tried and failed a preferred TNF antagonist and at least one conventional agent (e.g., methotrexate, sulfasalazine) for ≥ 3 months (chunk 5).

    Indications, Drug Background, and Definitions

    FDA indications
    FDA indication — plaque psoriasisModerate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
    FDA indication — psoriatic arthritisAdults with psoriatic arthritis (PsA)
    FDA indication — non-radiographic axSpAAdults with non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation
    FDA indication — ankylosing spondylitisAdults with active ankylosing spondylitis (AS)

    Bimzelx (bimekizumab) is a humanized monoclonal antibody that acts as an antagonist to both interleukin‑17A (IL‑17A) and interleukin‑17F (IL‑17F). It is FDA‑approved for certain adult inflammatory conditions including moderate‑to‑severe plaque psoriasis, psoriatic arthritis, non‑radiographic axial spondyloarthritis with objective signs of inflammation, and active ankylosing spondylitis. The policy references the prescribing information and available clinical trial evidence for safety and efficacy when assessing prior authorization requests.

    Policy Summary
    PayerAlaska Medicaid
    PolicyBimzelx (bimekizumab) prior authorization — coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and submit required baseline documentation (PASI or CASPAR, current weight, liver function tests) to support approval.
    SourceLink
    On This Page
    Coverage / Medical Necessity CriteriaSeverity Thresholds and Coding-relevant CriteriaPrior Authorization, Step Therapy, Documentation, and Denial ConditionsIndications, Drug Background, and Definitions
    nr-axSpA TNF Trial:
    5. Patient has tried and failed or has a documented clinical contraindication to a preferred TNF antagonist for at least 3 months
    Both overall BASDAI ≥ 4 and spinal pain component ≥ 4 are required for AS approval
    PASI (Psoriasis Area and Severity Index)
    DefinitionPsoriasis Area and Severity Index (PASI) — score used to quantify psoriasis severity
    Policy threshold for PSO approvalPASI score ≥ 10 (alternatively BSA ≥ 3%)
    Required baseline documentationPrescriber must provide PASI score at baseline
  1. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: tried and failed or documented contraindication to 2 different NSAIDs for ≥ 3 months AND tried and failed or contraindication to a preferred TNF antagonist for ≥ 3 months (chunks 7, 8).
  2. Documentation Required

    Required baseline documentation and approval durations

    Prescriber must submit baseline measures and labs with the PA request; initial approvals are up to 3 months and reauthorizations up to 12 months.

    • Plaque psoriasis baseline: PASI score, current patient weight, and liver function enzymes/alkaline phosphatase/bilirubin (chunk 4).
    • Psoriatic arthritis baseline: CASPAR score (or equivalent), current patient weight, and liver function enzymes/alkaline phosphatase/bilirubin (chunk 5).
    • Approval duration: Initial Approval up to 3 months; Reauthorization Approval up to 12 months (chunk 11).
    Denial Risk

    Denial triggers: missing criteria, infections, concurrent biologics, or active IBD

    Requests will be denied if approval criteria are not met, or if the patient has active clinically significant infection, is receiving another biologic response‑modifying agent, or has active inflammatory bowel disease.

    • Denial for failure to meet the specific approval criteria in the coverage sections (chunk 9).
    • Denial if patient has an active clinically significant infection (chunk 9).
    • Denial if patient is receiving another biologic response modifying agent (chunk 9).
    • Denial if patient has active inflammatory bowel disease (chunk 9).